Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer

Trial Profile

Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Rovalpituzumab tesirine (Primary)
  • Indications Neuroendocrine tumours; Small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Stem CentRx
  • Most Recent Events

    • 24 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2016 Results published in the Lancet Oncology
    • 01 Nov 2016 Results published in the Journal of Thoracic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top